Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

784 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emerging therapies in multiple sclerosis.
Farrell R, Heaney D, Giovannoni G. Farrell R, et al. Among authors: giovannoni g. Expert Opin Emerg Drugs. 2005 Nov;10(4):797-816. doi: 10.1517/14728214.10.4.797. Expert Opin Emerg Drugs. 2005. PMID: 16262563 Review.
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.
Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. Hartung HP, et al. Among authors: giovannoni g. J Neurol. 2007 Jul;254(7):827-37. doi: 10.1007/s00415-006-0486-3. Epub 2007 Apr 24. J Neurol. 2007. PMID: 17457510 Review.
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G, Hartung HP, Hemmer B, Hillert J, Kappos L, Killestein J, Lindberg R, Montalban X, Polman C, Sorensen PS; European NABINMS Consortium. Farrell R, et al. Among authors: giovannoni g. J Int Med Res. 2008 Jan-Feb;36(1):204-8; author reply 208-10. J Int Med Res. 2008. PMID: 18230281 No abstract available.
Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J. Lam R, et al. Among authors: giovannoni g. J Immunol Methods. 2008 Jul 31;336(2):113-8. doi: 10.1016/j.jim.2008.03.014. Epub 2008 May 1. J Immunol Methods. 2008. PMID: 18511063
NAbs reduce drug bioavailabity and high NAb titers reduce drug efficacy. We describe the validation of the R. Farrell and G. Giovannoni luciferase reporter gene assay to measure NAbs to INFbeta. ...
NAbs reduce drug bioavailabity and high NAb titers reduce drug efficacy. We describe the validation of the R. Farrell and G. Giova …
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Polman CH, et al. Among authors: giovannoni g. Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4. Lancet Neurol. 2010. PMID: 20610349
784 results